China (Mainland)
Nootropics Powders NSI 189 Phophate /Nsi-189 Phophate CAS 1270138-41-4 for Brain Improve CAS NO.1270138-40-3
- Min.Order: 10 Gram
- Payment Terms: T/T,Other
- Product Details
Keywords
- NSI-189
- NSI-189
- NSI-189
Quick Details
- ProName: Nootropics Powders NSI 189 Phophate /N...
- CasNo: 1270138-40-3
- Appearance: white powder
- Application: research for lab
- DeliveryTime: 2-3days
- ProductionCapacity: 500 Kilogram/Week
- Purity: 99.9%
- LimitNum: 10 Gram
- Moisture Content: 0.001%
- Impurity: 0.00001%
Superiority
linyi dingsheng chemical is an experienced enterprise of manufacturing various kind of apis, organic intermediates, research chemicals and peptide products.
linyi dingsheng ’s r&d center also offer custom synthesis services.
linyi dingsheng can provide different quantities of custom synthesis chemicals in lab, plant and industrial scale with more than fifteen years
1.we have over 10 years experience in this aera
2.we can provide competitive price for every customer and guarantee the quality of our goods.
3.we are attention to every customer's requirements and make a good relationship with them.
4.we have a long business relationship with many countries, such as canada, mexico, brazil, united kingdom, russia, germany, india, south africa, malta, egypt, armenia, australia, philippines, belgium, netherlands, denmark ect.
if you have any other questions to consult me.please not hesitate to contact me at any time.
we just produce and sell the products which are legal in china .and all products are only sold to labs for research.
Details
Pharmaceutical Raw Materials NSI-189 for Anti-depression CAS 1270138-40-3
molecular structure
Detail
CAS:1270138-40-3
MF:C22H30N4O
MW:366.4998
Model Number: CAS: 1270138-40-3
Minimum Order Quantity: 10g
Delivery Time: Usually within 7 work days
Payment Terms: , MoneyGram, Bank Transfer, Bitcoin
Certification: GMP,SGS,ISO9001:2008,KOSHER
Superiority
Yuanhang Bio-pharmaceutical Technology Co.,Ltd achieves millions of US dollars of salesrevenue in recent years. And there are currently over 400 employers, researchers accounting for 37%. We conducted more than 50 kinds of scientific research, and enjoy more than 20 national patents. We have even acquired national invention patent certificate. 5, 184 products of us are almost unique around the world. Our company's various raw chemical materials are of reliable quality, most of which conform to the requirements of FCC, USP and BP, it is mainly sold to pharmacy companies and health care companies abroad. Our target markets comprise of USA, Canada, UK, Brazil, Netherlands, Ireland, New Zealand, Austria, Australia and so on.
Description
NSI-189 is neurogenic and nootropic research agent that was developed from nicotinamide and pyrazine. Randomized controlled trials have shown that it stimulates neurogenesis or neuronal cell production in the brain. In animal studies, NSI-189 has also been shown to increase the volume of hippocampus by 20% thereby reversing behavioral symptoms of depression. Such studies have shown that it may be an effective treatment for depression. NSI-189 is also thought to be a promising treatment for other condition including post-traumatic stress disorder (PTSD), Alzheimer’s disease and age-related cognitive problems.
Neuralstem's technology enabled the creation of neural stem cell lines from many areas of the human CNS, including the hippocampus. The hippocampus is a part of the brain involved in memory and the generation of new neurons. It is also implicated in several major neurological and psychiatric diseases. From its hippocampal neural stem cell lines, Neuralstem has created virtually unlimited amounts of mature human neurons and glia in laboratory dishes. These can be used to mimic the natural brain environment in order to test drug effects.
COA
|
Product name |
NSI-189 |
||
| CAS No. |
1270138-40-3 |
Outer Packing | |
| Production date |
Dec. 15. 2016. |
Shelf life |
Dec. 14th. 2019 |
| Standard adopted |
in-house standard |
||
| Items of analysis | Specification | Results | |
|
Appearance |
Off-white powder |
Confrom |
|
|
Identification |
IR and HPLC spectrum shall conform to the standard sample |
conform |
|
|
Melting Point |
83ºC~86ºC |
84.3ºC~85.6ºC |
|
|
Loss on Drying |
Less than 0.5% |
0.29% |
|
|
Purity(On Dried Base,HPLC) |
NLT 99.5 % |
99.62% |
|
|
Total Impurity |
Less than 0.5% |
0.33% |
|
|
Residue On Ignition |
≤0.2% |
0.16% |
|
|
Heavy metal |
≤20ppm |
conform |
|
| Conclusion | Qualified | ||
Applicant
NSI-189 has been proved that is thought to potentially promote increased neuronal production whilst treat depression is NSI-189. This article discusses NSI-189 and how this novel nootropic agent can revolutionize the treatment for depression, and possibly other neurodegenerative disorders.
Current treatments for major depressive disorder (MDD) mostly include the use of oral medications to modulate critical neurotransmitters in the brain. Selective serotonin reuptake inhibitors (SSRIs) are believed to be the most commonly and widely prescribed treatment for depression. Most recent research however reveals that there is a new theory regarding the cause of major depressive disorder. This theory implicates that brain physiology also influences depression rather than brain chemistry problems alone.